This is the protocol for a review and there is no abstract. The objectives are as follows:
In this review, we aim to assess:
the benefits of fenoldopam therapy in preventing AKI among the hospitalised at-risk adult population;
the benefits of fenoldopam therapy in the treatment of hospitalised adult patients with AKI; and
any adverse events associated with fenoldopam therapy in patients with or at risk of AKI.
If you can't find a tool you're looking for, please click the link at the top of the page to "Go to old article view". Alternatively, view our Knowledge Base articles for additional help. Your feedback is important to us, so please let us know if you have comments or ideas for improvement.